Lonza Group AG
SIX:LONN
Intrinsic Value
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. [ Read More ]
The intrinsic value of one LONN stock under the Base Case scenario is 551.36 CHF. Compared to the current market price of 502.8 CHF, Lonza Group AG is Undervalued by 9%.
Valuation Backtest
Lonza Group AG
Run backtest to discover the historical profit from buying and selling LONN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Lonza Group AG
Current Assets | 4.9B |
Cash & Short-Term Investments | 1.7B |
Receivables | 1.2B |
Other Current Assets | 2.1B |
Non-Current Assets | 11.9B |
PP&E | 6.6B |
Intangibles | 4.7B |
Other Non-Current Assets | 589m |
Current Liabilities | 2.8B |
Accounts Payable | 468m |
Other Current Liabilities | 2.3B |
Non-Current Liabilities | 4.6B |
Long-Term Debt | 2.6B |
Other Non-Current Liabilities | 2B |
Earnings Waterfall
Lonza Group AG
Revenue
|
6.7B
CHF
|
Cost of Revenue
|
-4.3B
CHF
|
Gross Profit
|
2.4B
CHF
|
Operating Expenses
|
-1.1B
CHF
|
Operating Income
|
1.3B
CHF
|
Other Expenses
|
-677m
CHF
|
Net Income
|
654m
CHF
|
Free Cash Flow Analysis
Lonza Group AG
What is Free Cash Flow?
LONN Profitability Score
Profitability Due Diligence
Lonza Group AG's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Lonza Group AG's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
LONN Solvency Score
Solvency Due Diligence
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LONN Price Targets Summary
Lonza Group AG
According to Wall Street analysts, the average 1-year price target for LONN is 548.76 CHF with a low forecast of 328.25 CHF and a high forecast of 679.35 CHF.
Shareholder Return
LONN Price
Lonza Group AG
Average Annual Return | 17.45% |
Standard Deviation of Annual Returns | 41.53% |
Max Drawdown | -60% |
Market Capitalization | 36.2B CHF |
Shares Outstanding | 74 281 674 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 16,218 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Contact
IPO
Employees
Officers
The intrinsic value of one LONN stock under the Base Case scenario is 551.36 CHF.
Compared to the current market price of 502.8 CHF, Lonza Group AG is Undervalued by 9%.